Chemomab Therapeutics Ltd. Board of Directors

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is CM-101, a humanized monoclonal antibody attenuates the basic function of CCL24 that is in phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Dr. Adi Mor George Ph.D.

Dr. Adi Mor George Ph.D.

Co-Founder, Chief Scientific Officer, CEO & Executive Director

Barbara Lindheim

Barbara Lindheim

Consulting Vice President of Investor & Public Relations, Strategic Communications

Mr. Jack Lawler

Mr. Jack Lawler

Senior VP of Global Clinical Development Operations

Dr. Matthew B. Frankel M.B.A., M.D.

Dr. Matthew B. Frankel M.B.A., M.D.

Chief Medical Officer & VP of Drug Development

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.